Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994467 | 0.79 | SCN5A (0.39) | SCN5ASSTR4MAPK1GABRA1GABRG2 | |
| SCHEMBL938447 | 0.74 | SCN5A (0.54) | SCN5ASSTR4KDM4ENPC1MAPK1 | |
| SCHEMBL16506461 | 0.73 | KDM4E (0.38) | KDM4ENPC1MAPK1RAB9A | |
| SCHEMBL21355630 | 0.72 | KDM4E (0.32) | KDM4ENPC1MAPK1RAB9A | |
| SCHEMBL21713333 | 0.70 | SCN5A (0.41) | SCN5A | |
| SCHEMBL30628779 | 0.69 | ALDH1A1 (0.35) | KDM4ENPC1MAPK1RAB9A | |
| SCHEMBL1445037 | 0.69 | SCN5A (0.39) | SCN5A | |
| SCHEMBL31571142 | 0.69 | KDM4E (0.32) | KDM4ENPC1MAPK1RAB9A | |
| SCHEMBL16255847 | 0.68 | SSTR4 (0.51) | SSTR4NPC1MAPK1RAB9A | |
| SCHEMBL30864263 | 0.68 | PDE1C (0.35) | KDM4ENPC1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SCN5A 2332/4885SSTR4 3129/4885KDM4E 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.